Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Digital health software and connected health technology / Healthcare analytics, data infrastructure and interoperability / Life sciences and pharma data infrastructure, analytics and clinical decision support

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Life sciences and pharma data infrastructure, analytics and clinical decision support

Platforms bought by pharmaceutical and biotechnology companies to integrate clinical trial, real-world evidence and commercial data; run governed data platforms and analytics; and deploy AI-enabled clinical decision support and trial- or protocol-design tooling. Excludes discovery-stage wet-lab informatics and consumer health apps.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
75 /100
for B2B sellers
Evidence
not sized
3 sources · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Pharmaceutical and biotechnology companies (clinical development, medical affairs, RWE and commercial data functions)
Buying centre
Head of Clinical Data Sciences / VP Data and Analytics, with IT architecture, Medical Affairs and Regulatory leadership as influencers; centralised procurement with business-unit budget owners
Buying triggers
  • Launch of a new drug requiring trial and RWE data integration
  • Portfolio prioritisation and pipeline review decisions
  • Regulatory evidence requirements for label expansion or post-market surveillance
  • Enterprise data platform consolidation and cloud migration
Pains
  • Siloed clinical, trial and commercial data across business units
  • Reproducibility and validation burden for regulated analytics
  • Tension between speed of AI insight and GxP/validation requirements
  • High cost of bespoke data engineering for each programme
Scores (1–5)
Pain intensity3
Purchasing power5
Reachability3
Growth4

How this was sized

Not sized yet

Bottom-up proxy: source [1] gives a 2026 digital health market of USD 98.5bn with software at 62.0% (USD 61.1bn). Applying an assumed 4-7% share of that software pool to life-sciences data infrastructure, analytics and clinical decision support gives roughly USD 2.4-4.3bn (USD 2,400-4,300m); a wider 3-9% band gives USD 1.8-5.5bn. Indicative only, Low confidence: no source sizes this niche, and the source pool is provider-centric, so the share assumption carries wide error.

Alongside it in Healthcare analytics, data infrastructure and interoperability

// Sell into Life sciences and pharma data infrastructure, analytics and clinical decision support

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.